Status:
WITHDRAWN
Fabry and Cardiomyopathy (FaCard)
Lead Sponsor:
CENTOGENE GmbH Rostock
Conditions:
Cerebrovascular Accident
Stroke, Acute
Eligibility:
All Genders
18+ years
Brief Summary
Primary objective and endpoint is the analysis of the long-term course of lyso-Gb3 and its clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients.
Detailed Description
Fabry disease is an X-linked lysosomal disorder that leads to excessive deposition of neutral glycosphingolipids in the vascular endothelium of several organs in the body. Progressive endothelial accu...
Eligibility Criteria
Inclusion
- All patients of both gender from 18 years of age with a diagnosis of Fabry disease with the mutation N215S
- Written informed consent from patient
Exclusion
- Patients without a diagnosis of Fabry disease
- No written informed consent
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01429597
Start Date
July 1 2011
End Date
December 1 2019
Last Update
April 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration
Rostock, Germany, 18147